BCAS1 Antikörper (AA 542-584) (Cy3)

Produktnummer ABIN1409307

Produktdetails anti-BCAS1 Antikörper (Cy3)

Target: BCAS1 (Breast Carcinoma Amplified Sequence 1 (BCAS1))

Bindungsspezifität: AA 542-584

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser BCAS1 Antikörper ist konjugiert mit Cy3

Applikation: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Homologie: Human,Mouse,Rat

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human BCAS1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu BCAS1

Target: BCAS1 (Breast Carcinoma Amplified Sequence 1 (BCAS1))

Andere Bezeichnung: BCAS1/NABC1 (BCAS1 Produkte)

Synonyme: AIBC1 antikoerper, NABC1 antikoerper, 2210416M21Rik antikoerper, 9030223A09Rik antikoerper, AI841227 antikoerper, Band83 antikoerper, Pmes-2 antikoerper, BCAS1 antikoerper, MGC152145 antikoerper, breast carcinoma amplified sequence 1 antikoerper, BCAS1 antikoerper, Bcas1 antikoerper

Hintergrund:

Synonyms: AIBC 1, AIBC1, Amplied and overexpressed in breast cancer, BCAS 1, BCAS1, BCAS1_HUMAN, Breast carcinoma amplied sequence 1, Breast carcinoma-amplied sequence 1, Novel amplied in breast cancer 1.

Background: NaBC1 is a protein found amplified in most breast carcinoma forms. It is expressed primarily as a cytoplasmic, detergent-stable homodimer that has a tendency to interact with DYNLL1 (PIN) and DYNLL2. Breast tumor lines that exhibit 20q13.2 gene amplification express much higher levels of the protein as compared to the levels found in other breast cancer lines that do not overexpress the NaBC1 mRNA. However, this upregulation does not affect growth rate or anchoring abilities of a cell, indicating the oncogenic properties of NaBC1 differ from that of other oncogenes.